Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
  • C07K14/08—RNA viruses
  • C07K14/18—Togaviridae; Flaviviridae
  • C07K14/19—Rubella virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/785—Polymers containing nitrogen
  • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/28—Compounds containing heavy metals
  • A61K31/295—Iron group metal compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

• the present invention relates to a drug and method for proliferating natural killer cells, a method for producing natural killer cells and a method for screening for a substance having a natural killer cell proliferating action.
• the present invention is useful in the fields of medicine, food and so forth.
• Natural killer (NK) cells are a group of cells having a cytotoxic activity against various tumor cells, virus infected cells and cells having different major histocompatibility antigens, and their activation and inhibition are regulated primarily by receptors that recognize self and nonself.
• NK cells are considered to have important functions as one type of lymphocytes involved in natural immunity. Against viral infection, in particular, they play a very important role in immune responses in early infection until acquired immunity is established by T lymphocytes and B lymphocytes.
• NK cells As a method for obtaining NK cells from laboratory animals, a method of collecting cells from the spleen, blood, bone marrow and so forth and purifying them is known. However, since all of these tissues contain NK cells only in low proportions, technical skills and suitable equipment are required to secure NK cells necessary for experiments.
• lymphokine-activated killer lymphocytes LAK cells
• a method which comprises irradiating cells of the human B cell strain 721.221, in which the major histocompatibility class I (MHC-I) is hardly expressed on the cell surfaces, with a radioactive ray so that the cells should loose division potential, culturing the cells with monocular cells in peripheral blood as mixed culture for 5 to 6 days, purifying NK cells from the culture and further continuing culture to obtain a large amount of NK cells (e.g., Non-patent document 1).
• MHC-I major histocompatibility class I
• Patent document 1 a method for proliferating human NK cells comprising the step of mixed culture of peripheral blood mononuclear cells and cells of human fibroblast Wilms' tumor line HFWT
• Patent document 2 a method for enhancing an activity of animal natural killer lymphocytes utilizing conjugated linoleic acids as an active ingredient
• Patent document 2 a method for proliferating human NK cells by mixed culture of peripheral blood mononuclear cells and cells of human fibroblast Wilms' tumor line HFWT, and any method for collecting NK cells proliferated in vivo and screening for a factor that enhances the natural killer activity are not disclosed in this document.
• NK activity naturally killer activity, NK activity
• a method for measuring the NK activity in living bodies is a method of transplanting tumor cells radiolabeled in the same manner as mentioned above into a living body or infecting an animal with a virus or the like and observing the NK activity, and these methods require a special facility and equipment.
• Lactoferrin is known as a lactoprotein having various actions such as an antibacterial action, immunity activating action and antitumor action. Lactoferrin is a milk-derived glycoprotein that is highly safe and can be continuously taken for a long period of time. Since lactoferrin itself has almost no taste or odor, it is a highly versatile protein as an additive for various food, drugs and feeds.
• Patent document 3 International Patent Publication in Japanese (Kohyo) No. 2002-515893 proposes a method for stimulating NK cells in a patient which comprises the step of administering a composition containing a modified human lactoferrin to the patient.
• Patent document 3 does not describe the effect of the modified human lactoferrin for actually stimulating NK cells, and its basis has been unclear.
• the Toll-like receptors recognize various components of bacteria and are believed to play an important role not only in recognition of bacteria in natural immunity but also in activation of acquired immunity, and also considered to have functions of recognizing various pathogenic components and inducing unique responses.
• TLR Toll-like receptors
• the Toll-like receptor family in mammals consists of 10 family members, and pathogen-constituting components (ligands) recognized by each Toll-like receptor have been identified. These ligands, the pathogen-constituting components, include lipids, sugars, proteins, nucleic acids and so forth (Non-patent documents 2 and 3).
• An object of the present invention is to provide a technique of proliferating NK cells in vivo and a method for screening for a substance having an action of proliferating NK cells.
• the inventors of the present invention examined a method for screening for a food or drink-derived factor that enhances the NK activity, they administered lactoferrin, which is a food (milk)-derived factor, to an animal for a predetermined period, then administered a Toll-like receptor ligand with specific timing during the administration period, and found that the proportion of NK cells among the intraperitoneal cells markedly increased in the peritoneal cavity of the animal. Further, they found that since it became possible to induce NK cells in the peritoneal cavity by the aforementioned method, the NK activity could be easily analyzed and NK cells could be conveniently collected. Thus, they accomplished the present invention.
• the first invention of the present application that achieves the aforementioned object is a drug for proliferating animal NK cells, which comprises a first agent containing lactoferrin and a second agent containing a Toll-like receptor ligand, wherein the first agent and the second agent are separately packaged in the drug.
• the NK cell proliferating drug of the present invention is characterized by any of the following 1) to 3).
• the second invention of the present application is a method for proliferating NK cells in an animal (except for human), which comprises administering lactoferrin and a Toll-like receptor ligand to the animal.
• the NK cell proliferating method of the present invention is characterized by any of the following 4) to 6).
• the third invention of the present application is a method for producing NK cells, which comprises administering lactoferrin and a Toll-like receptor ligand to an animal (except for human), and collecting NK cells from the animal.
• the method for producing NK cells of the present invention is characterized by any of the following 7) to 9).
• the fourth invention of the present application is a method for screening for a substance having an action of proliferating NK cells in a living body of an animal (except for human), which comprises administering a test substance and a Toll-like receptor ligand to the animal and detecting induction of NK cells in the animal.
• the screening method of the present invention is characterized by any of the following 10) to 13).
• the fifth invention of the present application is use of lactoferrin and a Toll-like receptor ligand in the production of a drug for proliferating animal natural killer cells, wherein the aforementioned drug for proliferating animal natural killer cells comprises a first agent containing lactoferrin and a second agent containing a Toll-like receptor ligand, and the first agent and the second agent are separately packaged in the drug.
• the use of the present invention is characterized by any of the following 14) to 16).
• the animal NK cell proliferating drug of the present invention comprises a first agent containing lactoferrin and a second agent containing a Toll-like receptor ligand, wherein the first agent and the second agent are separately packaged in the drug.
• lactoferrin used for the present invention there can be used commercially available lactoferrin and lactoferrin obtained from colostrum, transitional milk, normal milk or late lactation milk of mammals (e.g., human, cow, goat, sheep, horse and so forth) or processed products of these milks such as skimmed milk and whey as a raw material and isolated from the aforementioned raw materials by a conventional technique such as ion exchange chromatography.
• commercially available lactoferrin produced in an industrial scale e.g., one produced by Morinaga Milk Industry Co., Ltd.
• lactoferrin produced in microorganisms, animal cells, transgenic animals and so forth by using genetic engineering techniques can also be used.
• modified lactoferrins of which amino acid sequence is changed or modified, are also encompassed in the lactoferrin of the present invention so long as the NK cell proliferating action of lactoferrin is not degraded.
• metal content in lactoferrin is not particularly limited, and there can be used any one type or a mixture of any two or more types selected from a group consisting of apolactoferrin obtained by deironizing lactoferrin with hydrochloric acid, citric acid or the like, metal-saturated lactoferrin with a saturation rate of 100% obtained by chelating the above-mentioned apolactoferrin with a metal such as iron, copper, zinc and manganese and partially metal-saturated lactoferrin to which a metal binds with various saturation rates lower than 100%.
• apolactoferrin obtained by deironizing lactoferrin with hydrochloric acid, citric acid or the like
• metal-saturated lactoferrin with a saturation rate of 100% obtained by chelating the above-mentioned apolactoferrin with a metal such as iron, copper, zinc and manganese and partially metal-saturated lactoferrin to which a metal binds
• any Toll-like receptor ligand can be used so long as the ligand recognizes one or more of the family members of Toll-like receptors 1 to 10 currently confirmed.
• lipopolysaccharides, ⁇ -glucans, double-stranded RNAs, polyinosinic-polycytidylic acid (polyIC) and anticancer agents such as taxol, defensin, heat shock proteins, fibrinogen, hyaluronic acid degradation products and so forth are preferred.
• PolyIC is particularly preferably used from a viewpoint of inducing and proliferating NK cells in an animal to which the NK cell proliferating drug of the present invention is administered, preferably in the peritoneal cavity of the animal.
• Toll-like receptor ligands that have not been confirmed to date can also be used for the present invention so long as they can proliferate animal NK cells together with lactoferrin.
• the aforementioned lactoferrin and Toll-like receptor ligand are separately packaged in the drug.
• separate packaging means that lactoferrin and a Toll-like receptor ligand are in a separated state so that they can be separately administered, and typically lactoferrin and the Toll-like receptor ligand are contained in separate containers, bags or the like.
• the first agent containing lactoferrin and the second agent containing a Toll-like receptor ligand are separately administered to an animal.
• the aforementioned first agent is preferably administered in an amount of 10 to 2000 mg/day, more preferably 100 to 1000 mg/day, per kg body weight of an animal in terms of the amount of lactoferrin.
• the method of administration is not particularly limited, oral administration is preferred.
• the aforementioned administration amount is preferably divided and administered one or more times per day everyday for 5 to 10 days, more preferably everyday for 7 to 8 days.
• the aforementioned second agent is preferably administered in an amount of 10 to 1000 ⁇ g/day, more preferably 50 to 200 ⁇ g/day, further preferably about 100 ⁇ g/day, per kg body weight of an animal in terms of the amount of the Toll-like receptor ligand.
• the second agent is preferably administered as a single dose of the aforementioned amount, and a single dose of about 100 ⁇ g/kg is particularly preferably administered.
• the method of administering the second agent is not particularly limited, intraperitoneal administration is preferred.
• the second agent is preferably administered once 5 to 2 days, preferably 3 days, before the completion of the administration of lactoferrin.
• the dosage forms of the first agent and the second agent are not particularly limited so long as they are prepared to be suitable for the aforementioned administration method and schedule. Further, the first agent and the second agent may contain other ingredients that do not adversely affect storage or impair actions of these ingredients, such as carriers, excipients and pH modifiers, in addition to lactoferrin and the Toll-like receptor ligand.
• the animal NK cell proliferating method of the present invention comprises administering lactoferrin and a Toll-like receptor ligand to an animal.
• Lactoferrin and the Toll-like receptor ligand may be the first agent and the second agent constituting the NK cell proliferating drug of the present invention, respectively.
• the aforementioned animal is not particularly limited so long as NK cells are induced and proliferated by administration of lactoferrin and a Toll-like receptor ligand, and examples thereof include mouse, rat, goat, sheep, horse, bovine and so forth.
• NK cells are induced and proliferated in the animal to which they have been administered.
• NK cells are induced in an organ or tissue to which the Toll-like receptor ligand is administered, for example, in the peritoneal cavity when the Toll-like receptor ligand is intraperitoneally administered.
• the preferred timing of administration of a Toll-like receptor ligand can be determined by performing a preliminary experiment so that NK cells should be efficiently induced in an animal used. That is, a suitable condition can be determined by administering a Toll-like receptor ligand to animals to which lactoferrin is administered everyday with changing the duration from the scheduled day of the completion of the administration of lactoferrin and comparing induction of NK cells. Once a suitable condition is determined, the administration schedule can be established according to this condition when the same type of animals are used.
• NK cells can be confirmed by, for example, using a labeled antibody that recognizes NK cells to measure the proportion of positive cells that react with the antibody among cells collected from an animal organ or tissue, for example, the peritoneal cavity.
• a labeled antibody that recognizes NK cells to measure the proportion of positive cells that react with the antibody among cells collected from an animal organ or tissue, for example, the peritoneal cavity.
• an anti-CD49b/Pan-NK cell antibody e.g., one produced by Pharmingen
• the proportion of cells positive for the CD49b/Pan-NK cell antibody can be measured to confirm NK cells.
• antigens of anti-mouse CD16/CD32 antibody or anti-rat CD32 antibody are preferably blocked by using these antibodies to reduce antibody binding via CD16/CD32 (Fc ⁇ III/II receptor) relating to the background.
• the proportion of NK1.1 positive cells is preferably measured by using the anti-NK1.1 antibody as an antibody that recognizes NK cells.
• cells can be stained by using FITC-labeled NK1.1 antibodies, and the proportion of NK1.1 positive cells can be measured by using a flow cytometer (e.g., FACSTM Calibur, Becton, Dickinson and Company).
• NK cells can be prepared by collecting NK cells from an animal in which NK cells are proliferated as described above. NK cells can be collected from the animal at a time point at which NK cells are expected to be efficiently induced according to a predetermined administration schedule. After administration of lactoferrin, animals may be left for one day without administering anything, and proliferated NK cells may be collected thereafter.
• NK cells can be collected in a conventional manner. For example, when NK cells are induced in the peritoneal cavity, they can be collected by washing the peritoneal cavity of the animal once or several times with a washing solution (e.g., Hank's solution) and collecting the washing solution.
• a washing solution e.g., Hank's solution
• a method of using a cell sorter can be used, for example.
• NK cells obtained by the method of the present invention are expected to maintain a high cytotoxic activity.
• NK cells are known to have an antiviral activity or antitumor activity. Therefore, NK cells obtained by the method of the present invention can be used for, for example, cell therapy against infection with viruses such as herpes virus and cytomegalovirus as well as the LAK (lymphokine activated killer) therapy for cancer patients.
• viruses such as herpes virus and cytomegalovirus
• LAK lymphokine activated killer
• the NK cell proliferating action of lactoferrin was enhanced by administration of a Toll-like receptor ligand. Therefore, by using a Toll-like receptor ligand, the action of a substance having an NK cell proliferating action can be enhanced, and screening can be performed for a substance having an NK cell proliferating action with high sensitivity. That is, screening can be performed for a substance having an NK cell proliferating action by administering a test substance and a Toll-like receptor ligand to an animal and detecting induction of NK cells in the animal.
• test substance instead of lactoferrin, and a Toll-like receptor ligand are administered to an animal according to the schedule for administration of lactoferrin determined as described above, if NK cells are induced in the animal, the aforementioned test substance is considered to have an NK cell proliferating action.
• the administration method may be similar to that for the NK cell proliferating drug of the present invention.
• the test substance is orally administered, and a Toll-like receptor ligand is intraperitoneally administered.
• induction of NK cells can be detected by, for example, using a labeled antibody that recognizes NK cells and measuring the proportion of positive cells that react with the antibody as described above.
• test substance examples include food and drink such as milk of animals and various components of these food and drink.
• a substance having an NK cell proliferating action found by the screening method of the present invention in particular, food or a component thereof, can be utilized as a drug, health food or a component thereof intended to be used for proliferation of NK cells or prophylactic treatment of a disease that can be prevented by proliferation of NK cells.
• mice Forty five 7-week old C57BL/6 mice (purchased from Charles River Laboratories Japan, Inc.) were divided into 5 groups, each consisting of 9 animals, acclimatized and fed for 1 week.
• the aforementioned cell suspension was added with 10 ⁇ l per specimen of anti-mouse CD16/CD32 monoclonal antibody (Fc BlockTM, Becton, Dickinson and Company) solution diluted to a concentration of 1 ⁇ g/10 ⁇ l with a Cell Wash (Becton, Dickinson and Company) solution containing 1% bovine fetal serum (henceforth referred to as “dilution buffer”) and left standing on ice for 5 minutes to block the Fc ⁇ III/II receptor.
• Fc BlockTM Anti-mouse CD16/CD32 monoclonal antibody
• dilution buffer bovine fetal serum
• the mixture was added with 10 ⁇ l of FITC-labeled anti-mouse NK1.1 antibody (Pharmingen) solution adjusted to a concentration of 1 ⁇ g/10 ⁇ l with the dilution buffer, mixed and left standing for 25 minutes to stain NK1.1 positive NK cells. Subsequently, the mixture was added with 500 ⁇ l of the dilution buffer and centrifuged at 3500 rpm for 5 minutes to wash the cells, and this washing procedure was repeated twice. Then, the cells were added with 500 ⁇ l of FACSTM Lysing Solution (Becton, Dickinson and Company) and left standing at room temperature for 10 minutes to dissolve erythrocytes.
• FACSTM Lysing Solution Becton, Dickinson and Company
• the cells were washed twice according to the aforementioned washing procedure, and recovered cells were added with 1 ml of the dilution buffer to prepare a cell suspension.
• the prepared cell suspension was filtered through a nylon screen (Flon Industry Co., Ltd., Product No.: F-3100-134) and collected in a polystyrene tube, and the proportion of NK1.1 positive cells was measured by using a flow cytometer (FACSTM Calibur, Becton, Dickinson and Company).
• mice per group 63 mice in total, were acclimatized and fed for 1 week.
• 3 groups were assigned lactoferrin administration groups (LF groups, dose of lactoferrin: 300 mg/kg body weight/day), and the remaining 4 groups were assigned control groups (physiological saline was administered).
• An administration schedule was designed, in which each sample (lactoferrin or physiological saline) was administered everyday for 7 days to mice in all the 7 groups by using an oral sonde, then nothing was administered for 1 day, and the 8th day was assumed as the day of completion of the administration.
• mice were intraperitoneally administered with 100 ⁇ g of polyIC (Polyinosinic-Polycytidylic Acid Sodium Salt, Product No.: P-0913, Sigma) 7 days, 3 days or 1 day before completion of the administration were assigned, respectively, and the remaining one control group was assigned a group administered with no polyIC for use in the test.
• polyIC Polyinosinic-Polycytidylic Acid Sodium Salt, Product No.: P-0913, Sigma
• NK cells could be specifically induced in the peritoneal cavity, and the proportion and the absolute number of NK cells could be markedly increased, in particular, in the administration schedule of administering lactoferrin everyday for 7 days and completing the administration on the 8th day, by administering polyIC 3 days before completion of the administration.
• NK cells were proliferated at least in the spleen by oral administration of lactoferrin, and that NK cells were induced in the peritoneal cavity by further intraperitoneally administering polyIC. From the above, it is considered that if another substance having an action of proliferating NK cells in a living body of an animal is administered instead of lactoferrin, and a Toll-like receptor ligand such as polyIC is, for example, intraperitoneally administered, NK cells are also induced in the peritoneal cavity. It is considered that such induction of NK cells using a substance having an NK cell proliferating action and a Toll-like receptor ligand in combination can be utilized in screening for a substance having an NK cell proliferating action.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Virology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (2)

Publications (1)

Family

ID=36059930

Family Applications (3)

Family Applications After (2)

Country Status (10)

Families Citing this family (2)

Family Cites Families (5)

• 2005
  • 2005-09-07 KR KR1020077011584A patent/KR101059724B1/ko not_active IP Right Cessation
  • 2005-09-07 NZ NZ546174A patent/NZ546174A/en not_active IP Right Cessation
  • 2005-09-07 CN CN2005800014130A patent/CN1897973B/zh not_active Expired - Fee Related
  • 2005-09-07 JP JP2006535800A patent/JP3970916B2/ja not_active Expired - Fee Related
  • 2005-09-07 US US10/573,564 patent/US20070116675A1/en not_active Abandoned
  • 2005-09-07 CN CN200910161192A patent/CN101658678A/zh active Pending
  • 2005-09-07 EP EP11183460.2A patent/EP2402034B1/en not_active Expired - Fee Related
  • 2005-09-07 AU AU2005256118A patent/AU2005256118B8/en not_active Ceased
  • 2005-09-07 CA CA2544155A patent/CA2544155C/en not_active Expired - Fee Related
  • 2005-09-07 EP EP05782272A patent/EP1790355B1/en not_active Expired - Fee Related
  • 2005-09-07 KR KR1020067006653A patent/KR100835877B1/ko not_active IP Right Cessation
  • 2005-09-07 WO PCT/JP2005/016449 patent/WO2006030675A1/ja active IP Right Grant
• 2007
  • 2007-01-23 JP JP2007012541A patent/JP4537413B2/ja not_active Expired - Fee Related
  • 2007-11-15 HK HK07112502.9A patent/HK1103987A1/xx not_active IP Right Cessation
  • 2007-11-15 HK HK12103648.6A patent/HK1162954A1/xx not_active IP Right Cessation
• 2008
  • 2008-07-25 US US12/179,898 patent/US7629316B2/en not_active Expired - Fee Related
  • 2008-07-25 US US12/179,878 patent/US7628976B2/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events